6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

December 6, 2024

________________

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

The European Commission approves the acquisition of Catalent by Novo Holdings and the relatedacquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Bagsværd, Denmark, 6 December 2024— Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.

On 29 May 2024, Catalent stockholders voted to approve the pending transaction. Moreover, the acquisition has been approved by the authorities in a number of jurisdictions.

The completion of the acquisition remains subject to the fulfilment of further customary closing conditions, including regulatory approvals in other jurisdictions. Novo Nordisk still expects the acquisition to be completed towards the end of 2024.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered inDenmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneeringscientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employsabout 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.